Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Specific oncogenic drivers differently shaped the composition and functional diversity of immune cells in the microenvironment of experimental gliomas

ABSTRACT: Specific oncogenic drivers differently shaped the composition and functional diversity of immune cells in the microenvironment of experimental gliomas

PROVIDER: PRJNA1122489 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Specific oncogenic drivers differently shaped the composition and functional diversity of immune cells in the microenvironment of experimental gliomas

Project description:We performed spatial transcriptomics to profile spatial localization and intercations of cell populations within GL261 glioma mouse model.

2025-09-12 | GSE269545 | GEO

Recurrent FGFR-alterations are frequent oncogenic drivers and therapeutic targets in pediatric low-grade gliomas [scRNA-seq]

Project description:Alterations in Fibroblast growth factor receptor proteins frequently occur as oncogenes in many cancers. FGFR alterations have been reported in a subset of pediatric gliomas, representing a therapeutic target for precision medicine approaches. We performed a genomic analysis of 13,659 gliomas and found that 4.5% harbor FGFR alterations including structural variants and single nucleotide variants. FGFR family members are differentially enriched by age, tumor grade, and histological subtype. FGFR1 alterations are most frequent in pediatric gliomas, particularly pediatric low-grade gliomas, while FGFR3 drivers were associated with adult gliomas. In vitro and in vivo functional studies confirm FGFR1 alterations to be sufficient to activate MAPK and mTOR signaling, drive gliomagenesis and activate neuronal transcriptional programs. FGFR1-driven models showed sensitivity to MAPK pathway inhibitors, including panFGFR inhibitors that are FDA approved for use in other cancers. While early FGFR inhibition was sufficient to prolong survival of mice bearing FGFR-driven xenografts, this was insufficient to induce cures. Similarly, review of patients treated with currently available MAPK pathway or FGFR inhibitors revealed modest responses. This study provides key insights into the biology of FGFR1-altered gliomas and potential strategies to therapeutically target them.

2025-05-16 | GSE273990 | GEO

Recurrent FGFR-alterations are frequent oncogenic drivers and therapeutic targets in pediatric low-grade gliomas [RNA-seq]

2025-05-16 | GSE273989 | GEO

Recurrent FGFR-alterations are frequent oncogenic drivers and therapeutic targets in pediatric low-grade gliomas [RNA-Seq 2]

2025-05-16 | GSE286565 | GEO

Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas

Project description:Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas

| PRJNA1129199 | ENA

Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas

Project description:Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas

| PRJNA1129197 | ENA

Recurrent FGFR-alterations are frequent oncogenic drivers and therapeutic targets in pediatric low-grade gliomas

Project description:Recurrent FGFR-alterations are frequent oncogenic drivers and therapeutic targets in pediatric low-grade gliomas

| PRJNA1144947 | ENA

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Project description:This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), brain tumors with a high number of genetic mutations, ependymoma or medulloblastoma that have come back (recurrent), progressed, or have not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body’s immune system, and may interfere with the ability of tumor cells to grow and spread.

| 2183538 | ecrin-mdr-crc

Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas

Project description:Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas

| PRJNA714986 | ENA

Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas

Project description:Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas

| PRJNA714988 | ENA